Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression — Dan Joseph Stein (2013) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression
Shared by
Dan Joseph Stein
Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression
Article
2013
en
Authors
Dan Joseph Stein
FP
F. Picarel-Blanchot
SK
Sidney H. Kennedy
Abstract
1 min read
Once-a-day oral agomelatine is a new, efficacious alternative option for the treatment of anxiety in patients with major depression.
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2023
Evidence-Based Pharmacotherapy of Anxiety Symptoms in Patients with Major Depressive Disorder: Focus on Agomelatine
Dan Joseph Stein
Article
2021
Evidence-Based Pharmacotherapy of Generalised Anxiety Disorder: Focus on Agomelatine
Dan Joseph Stein
Article
2008
Efficacy of Agomelatine in Generalized Anxiety Disorder
Dan Joseph Stein
,
Antti Ahokas
,
Christian de Bodinat
Article
2011
Long-term treatment with agomelatine: prevention of relapse in patients with generalised anxiety disorder over 6 months
Dan Joseph Stein
,
Antti Ahokas
,
Christer Allgulander
,
J. Soegaard
,
István Bitter
,
Andres Lehtmets
,
Kurt Wahlstedt
,
Michael Van Amerigen
Article
2017
Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study
Dan Joseph Stein
,
Antti Ahokas
,
Marek Jarema
,
А С Аведисова
,
L. Vavrušová
,
Олег Чабан
,
C. Gruget
,
Valérie Olivier
,
F. Picarel-Blanchot
,
Christian de Bodinat
Discussion(0)
No comments yet. Be the first to comment.